NCT00981240View on ClinicalTrials.gov

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

SAR103168

"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"

Trial Locations (3)

10021

Sanofi-Aventis Investigational Site Number 840002, New York

30322

Sanofi-Aventis Investigational Site Number 840003, Atlanta

77030

Sanofi-Aventis Investigational Site Number 840001, Houston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY